Full Breakdown
Eli Lilly's Foundayo: A Breakthrough in Cardiovascular Safety for Diabetes Treatment
4/16/2026, 10:00:19 PM
Key Findings from the ACHIEVE-4 Trial
Eli Lilly & Co. has announced significant results from its Phase 3 trial, known as ACHIEVE-4, which evaluated the cardiovascular safety and health benefits of its new oral weight-loss medication, Foundayo (orforglipron). Conducted among over 2,700 participants across 15 countries, the trial compared Foundayo to insulin glargine, a long-acting insulin, in patients with type 2 diabetes who are overweight or obese and at increased cardiovascular risk. The study demonstrated that Foundayo had a non-inferior risk of major adverse cardiovascular events (MACE-4), which include cardiovascular death, heart attack, and stroke, showing a 16% reduction in risk compared to insulin glargine.
Additionally, the trial revealed a 57% lower risk of all-cause mortality for patients taking Foundayo. The findings underscore the drug's potential to enhance cardiometabolic health among diabetic patients. After 52 weeks, patients using Foundayo experienced an average A1C reduction of 1.6%, compared to a 1.0% reduction for those on insulin glargine. Furthermore, participants taking Foundayo lost an average of 17.9 pounds, while those on insulin glargine gained approximately 3.1 pounds.
Regulatory Plans and Market Implications
Following these promising results, Eli Lilly plans to submit Foundayo for U.S. Food and Drug Administration (FDA) approval for type 2 diabetes treatment by the end of the second quarter of 2026. This submission will utilize the Commissioner’s National Priority Review Voucher program, which aims to expedite access to critical medications. The FDA had previously requested additional safety data regarding cardiovascular and liver health as a condition for Foundayo's approval for weight management, which was granted just weeks before the trial results were announced.
The approval of Foundayo intensifies competition with Novo Nordisk A/S, whose oral weight-loss medication, Wegovy, has been on the market since January. Analysts suggest that Foundayo's approval for diabetes could occur earlier than initially expected, potentially impacting market dynamics significantly.
Safety Profile and Side Effects
The safety profile of Foundayo aligns with previous studies of the GLP-1 drug class, with common side effects including nausea, vomiting, and decreased appetite. Notably, a specific analysis for drug-induced liver injury found no safety concerns. However, the FDA has directed Lilly to conduct further studies to evaluate potential issues related to gastric emptying and pulmonary aspiration risks.
Criticism & Opposition
Despite the positive findings, some analysts caution that further statistical work is needed to confirm the results, particularly regarding the observed reductions in mortality. The FDA's requirement for additional data reflects ongoing concerns about the drug's safety profile, particularly in relation to liver health.
What's Next
Eli Lilly is committed to addressing cardiometabolic health challenges through ongoing research and innovation. The company is also exploring Foundayo's potential applications in other conditions, such as obstructive sleep apnea and hypertension, beyond its current indications for weight management and the pending diabetes use.
As the pharmaceutical landscape evolves, the outcomes of the ACHIEVE-4 trial position Foundayo as a promising new therapeutic option for individuals with type 2 diabetes, potentially reshaping treatment paradigms in this area.
